MRK

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 18

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,800

Underlying: Common Stock · 24,800 shares

Expires 2019-04-23

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 17

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,800

Underlying: Common Stock · 24,800 shares

Expires 2018-02-28

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 16

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2017-03-01

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 15

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,334

Underlying: Common Stock · 13,334 shares

Expires 2016-03-02

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 14

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,334

Underlying: Common Stock · 3,334 shares

Expires 2016-01-31

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 13

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,099

Underlying: Common Stock · 21,099 shares

Expires 2011-03-01

F5 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 12

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,834

Underlying: Common Stock · 5,834 shares

Expires 2015-02-24

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 11

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,334

Underlying: Common Stock · 3,334 shares

Expires 2014-10-31

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 10

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2014-05-02

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 9

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2014-02-26

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 8

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,319

Underlying: Common Stock · 25,319 shares

Expires 2010-02-21

F5 · price: This option, which vesting on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 7

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,374

Underlying: Common Stock · 26,374 shares

Expires 2013-02-27

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 6

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,989

Underlying: Common Stock · 18,989 shares

Expires 2012-02-29

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 5

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,650

Underlying: Common Stock · 4,650 shares

Expires 2012-04-24

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 4

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,722

Underlying: Common Stock · 16,722 shares

Expires 2011-09-01

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions.

SEC source: 0001225208-09-021927 · doc4.xml · derivative · entry 3

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,650

Underlying: Common Stock · 4,650 shares

Expires 2011-02-28

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions.

SEC source: 0001225208-09-021927 · doc4.xml · nonDerivative · entry 2

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 86

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021927 · doc4.xml · nonDerivative · entry 1

Turner Mervyn · CIK 0001475383 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By 401(k)

Disclosed balance after: 1,221.8905

F1 · price: Received as part of the Transactions in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. ("MSD") common stock held under the MSD 401(k) plan.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 15

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,008

Underlying: Common Stock · 5,192 shares

Expires 2016-04-30

F18 · derivative.exercise_price: The option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 14

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,001

Underlying: Common Stock · 4,999 shares

Expires 2015-04-30

F17 · derivative.exercise_price: The option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 13

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,230

Underlying: Common Stock · 8,770 shares

Expires 2014-04-30

F16 · derivative.exercise_price: The option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 12

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,230

Underlying: Common Stock · 8,770 shares

Expires 2013-05-18

F15 · derivative.exercise_price: The option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 11

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,230

Underlying: Common Stock · 8,770 shares

Expires 2015-04-24

F14 · derivative.exercise_price: The option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 10

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,861

Underlying: Common Stock · 6,139 shares

Expires 2014-02-22

F13 · derivative.exercise_price: The option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 9

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,916

Underlying: Common Stock · 5,184 shares

Expires 2013-02-23

F12 · derivative.exercise_price: The option price for the grant expiring 2/23/13 will convert from $17.85 to $19.57.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 8

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,474

Underlying: Common Stock · 3,026 shares

Expires 2012-02-24

F11 · derivative.exercise_price: The option price for the grant expiring 2/24/12 will convert from $34.68 to $38.01.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 7

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,474

Underlying: Common Stock · 3,026 shares

Expires 2011-02-25

F10 · derivative.exercise_price: The option price for the grant expiring 2/25/11 will convert from $40.05 to $43.90.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 6

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,914

Underlying: Common Stock · 10,086 shares

Expires 2010-09-24

F9 · derivative.exercise_price: The option price for the grant expiring 9/24/10 will convert from $45.04 to $49.37.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 5

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,617

Underlying: Common Stock · 1,983 shares

Expires 2010-02-21

F8 · derivative.exercise_price: The option price for the grant expiring 2/21/10 will convert from $37.75 to $41.38.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 4

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,230

Underlying: Common Stock · 8,770 shares

Expires 2009-12-05

F5 · derivative.exercise_price: The option price for the grant expiring 12/05/09 will convert from $47.875 to $52.48.

F7 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F6 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021935 · doc4.xml · derivative · entry 3

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,380

Underlying: Common Stock · 28,172 shares

Expires not disclosed

F3 · derivative.exercise_price: Each unit was the economic equivalent of one share of Schering-Plough Corporation common stock.

F4 · price: In connection with the Transactions, each share held in the Schering-Plough Corporation stock fund prior to the Transactions of Schering-Plough Corporation's Savings Advantage Plan was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. The plan continues following the Transactions and both the shares and cash will remain in the plan until such time as a disposition is made to the reporting person under the terms of the plan.

F4 · derivative.exercise_date: In connection with the Transactions, each share held in the Schering-Plough Corporation stock fund prior to the Transactions of Schering-Plough Corporation's Savings Advantage Plan was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. The plan continues following the Transactions and both the shares and cash will remain in the plan until such time as a disposition is made to the reporting person under the terms of the plan.

F4 · derivative.expiration_date: In connection with the Transactions, each share held in the Schering-Plough Corporation stock fund prior to the Transactions of Schering-Plough Corporation's Savings Advantage Plan was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. The plan continues following the Transactions and both the shares and cash will remain in the plan until such time as a disposition is made to the reporting person under the terms of the plan.

SEC source: 0001225208-09-021935 · doc4.xml · nonDerivative · entry 2

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Indirect · By 401(k)

Disclosed balance after: 3,298

F2 · price: In connection with the Transactions, each share held in the Schering-Plough Corporation stock fund prior to the Transactions of Schering-Plough Corporation's 401(k) plan was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. The plan continues following the Transactions and both the shares and cash will remain in the plan until such time as a disposition is made to the reporting person under the terms of the plan.

SEC source: 0001225208-09-021935 · doc4.xml · nonDerivative · entry 1

KOHAN RAUL E · CIK 0001238302 · Exe V-P & Pres, Animal Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,274

F1 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-022318 · doc4.xml · derivative · entry 12

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2019-04-30

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-022318 · doc4.xml · derivative · entry 11

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2018-04-29

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-022318 · doc4.xml · derivative · entry 10

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2017-04-26

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-022318 · doc4.xml · derivative · entry 9

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2016-04-27

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-022318 · doc4.xml · derivative · entry 8

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2015-04-28

F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger.

SEC source: 0001225208-09-022318 · doc4.xml · derivative · entry 7

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,648.7403

Underlying: Common Stock · 19,648.7403 shares

Expires not disclosed

F3 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F3 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

F3 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions.

SEC source: 0001225208-09-022318 · doc4.xml · nonDerivative · entry 6

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,757

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-022318 · doc4.xml · nonDerivative · entry 5

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,800

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-022318 · doc4.xml · nonDerivative · entry 4

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · As Custodian

Disclosed balance after: 530

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-022318 · doc4.xml · nonDerivative · entry 3

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · As Custodian

Disclosed balance after: 700

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-022318 · doc4.xml · nonDerivative · entry 2

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,595

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-022318 · doc4.xml · nonDerivative · entry 1

LAZARUS ROCHELLE B · CIK 0001082206 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions").

SEC source: 0001225208-09-024286 · doc4a.xml · derivative · entry 2

Thompson Craig B. · CIK 0001423419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 747.2123

Underlying: Common Stock · 747.2123 shares

Expires not disclosed

F3 · derivative.exercise_price: 1-for-1

F4 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F4 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001225208-09-024286 · doc4a.xml · nonDerivative · entry 1

Thompson Craig B. · CIK 0001423419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,814

F1 · shares: The line item is not new or revised, but was reported in error, and the purpose of this amendment is to delete the specified item.

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

F1 · balance_after: The line item is not new or revised, but was reported in error, and the purpose of this amendment is to delete the specified item.

SEC source: 0001225208-09-024624 · doc4.xml · derivative · entry 1

RUSSO PATRICIA F · CIK 0001023219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 747.2123

Underlying: Common Stock · 747.2123 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001225208-09-024625 · doc4.xml · derivative · entry 1

KIDDER C ROBERT · CIK 0001179703 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 747.2123

Underlying: Common Stock · 747.2123 shares

Expires not disclosed

F1 · derivative.exercise_price: 1-for-1

F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

SEC source: 0001209191-10-005614 · doc4a.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,580

F3 · shares: Pursuant to the terms of the Issuer's 2006 Stock Incentive Plan, the shares will become payable on December 31, 2011 provided that the reporting person remains continuously employed by the Issuer through that date, or, if sooner, upon the reporting person's involuntary termination of employment other than for cause.

F2 · balance_after: Reflects beneficial ownership as of November 3, 2009.